-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompileKe Ke
On May 11, Eli Lilly and MiNA Therapeutics, an RNA activation therapy company, announced a global research collaboration to develop new drug candidates using MiNA's proprietary small molecule activated RNA (saRNA) technology platform.
According to the terms of the agreement, MiNA will use its saRNA platform to research five targets selected by Eli Lilly, aimed at addressing diseases in Lilly's key therapeutic areas.
At the same time, Biogen and Capsigen also announced that they have reached a strategic research cooperation to design a new adeno-associated virus (AAV) capsid, which may provide transformative gene therapy to solve the problem.
As part of the collaboration, Capsigen’s patented TRADE™ platform and related technologies will be used to create and identify new AAV capsids to meet disease-specific transduction profiles.
Under the terms of the agreement, Capsigen will apply its vector engineering methods to develop new capsids to meet highly customized disease-specific transduction profiles.
Reference source:
Reference source:1.
1.
2.
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders